bay-63-2521 and omecamtiv-mecarbil

During the last 20 years, the prognosis for heart failure (HF) with reduced ejection fraction has steadily improved due to advances in drug treatment and the consistent implementation of guideline-recommended evidence-based drug therapy. Nevertheless, the morbidity and mortality rates of patients with HF can still be improved. The prevalence of HF is high and continues to increase steadily. Thus, timely and efficient drug treatment plays a central role in improving the quality of life and prognosis for patients with HF. Current therapeutic concepts combine inhibition of the renin-angiotensin-aldosterone system with blockage of the sympathetic system. New therapeutic approaches such as selective heart rate reduction, attenuation of the degradation of natriuretic peptides by neutral endopeptidase inhibition and treatment of comorbidities (e.g. iron deficiency, diabetes mellitus, hyperkalaemia) have led to a further improvement in the survival, time-out-of hospital and quality of life of affected patients. The goal of this article was to give an overview of the current standard drug therapy for HF and the value of new therapeutic approaches implemented in recent years.

Topics: Adrenergic beta-Antagonists; Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzhydryl Compounds; Cardiac Glycosides; Cardiotonic Agents; Diuretics; Enzyme Activators; Glucosides; Heart Failure; Humans; Hyperkalemia; Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels; Iron; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Practice Guidelines as Topic; Pyrazoles; Pyrimidines; Renin; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Urea